Stellar Capital Management LLC trimmed its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 0.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,506 shares of the medical research company’s stock after selling 155 shares during the period. Quest Diagnostics accounts for 2.2% of Stellar Capital Management LLC’s holdings, making the stock its 18th biggest position. Stellar Capital Management LLC’s holdings in Quest Diagnostics were worth $3,058,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sun Life Financial INC lifted its holdings in Quest Diagnostics by 14,142.9% during the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after purchasing an additional 990 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Quest Diagnostics by 16.1% during the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 177 shares in the last quarter. Acrospire Investment Management LLC lifted its holdings in Quest Diagnostics by 300.0% during the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after purchasing an additional 1,200 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Quest Diagnostics during the second quarter valued at $180,000. Finally, Financial Architects Inc lifted its holdings in Quest Diagnostics by 5.6% during the second quarter. Financial Architects Inc now owns 1,666 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 88 shares in the last quarter. 87.10% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Quest Diagnostics Incorporated (DGX) Holdings Cut by Stellar Capital Management LLC” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/11/quest-diagnostics-incorporated-dgx-holdings-cut-by-stellar-capital-management-llc.html.

In other Quest Diagnostics news, Director Jeffrey M. Leiden sold 1,304 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $108.73, for a total value of $141,783.92. Following the transaction, the director now directly owns 6,296 shares in the company, valued at approximately $684,564.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Stephen H. Rusckowski sold 59,235 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $108.16, for a total transaction of $6,406,857.60. Following the completion of the transaction, the chairman now owns 220,049 shares in the company, valued at $23,800,499.84. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 161,996 shares of company stock worth $17,517,207. 1.75% of the stock is owned by insiders.

Quest Diagnostics Incorporated (NYSE DGX) traded up 0.90% during midday trading on Wednesday, reaching $91.68. 297,517 shares of the company traded hands. The firm has a market capitalization of $12.51 billion, a PE ratio of 18.48 and a beta of 0.65. Quest Diagnostics Incorporated has a 12 month low of $79.12 and a 12 month high of $112.96. The company’s 50-day moving average price is $101.50 and its 200 day moving average price is $104.98.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.13. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. On average, equities analysts anticipate that Quest Diagnostics Incorporated will post $5.66 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd will be issued a $0.45 dividend. The ex-dividend date is Monday, October 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 1.98%. Quest Diagnostics’s dividend payout ratio (DPR) is 36.29%.

Several equities analysts have issued reports on DGX shares. Canaccord Genuity reaffirmed a “buy” rating and set a $118.00 price objective on shares of Quest Diagnostics in a report on Tuesday, June 13th. Evercore ISI reaffirmed an “in-line” rating and set a $104.50 price objective on shares of Quest Diagnostics in a report on Wednesday, June 28th. BidaskClub raised shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 29th. UBS AG increased their price objective on shares of Quest Diagnostics from $115.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $110.00 price objective (up from $83.00) on shares of Quest Diagnostics in a report on Thursday, July 13th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $110.41.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Stock Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related stocks with our FREE daily email newsletter.